11 Deer Park Drive, Suite 208
Monmouth Junction, NJ 08852
X-Cell Medical Inc.
X-Cell Medical's mission is to discover and develop alternative drugs for device-drug combinations, believing that the drug in such combination products is the most valuable component. The company has in-house expertise in drug discovery, formulation, and polymer coatings, as well as a deep set of cardiovascular device experience, coming from its medical advisory board, which consists of some of the most influential cardiology device users in the world.
More from R&D
• By
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
• By
Oral RNA splicing modulator has gone into a Phase II/III trial
• By
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
More from Scrip
• By
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
• By
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
• By
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.